Life span of carbamylated red cells in sickle cell anemia.

Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Print ISSN: 0021-9738 (Print) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.

Erythrocyte Aging* ; Isoflurophate*; Anemia, Sickle Cell/*blood ; Carbamates/*blood; Adolescent ; Adult ; Carbon Radioisotopes ; Erythrocytes/metabolism ; Female ; Humans ; Male ; Phosphorus Radioisotopes ; Tritium

By using three isotopes of diisopropyl-phosphofluoridate ([(3)H]-, [(14)C]-, and [(32)P]DFP) simultaneously, the life span of red cells from 20 patients with sickle cell anemia (Hb SS) has been studied after varying degrees of carbamylation in vitro with cyanate (NCO) and carbamyl phosphate (CP). The results are expressed in terms of the red cell mean life span (MLS). The MLS of red cells in the patients studied averaged 15.2+/-6.3 (SD) days. After carbamylation the increase in red cell life span was linearly proportional to the concentration of cyanate used, so that at 0.01. 0.02, and 0.3 M NCO (approximately 1, 1.6, and 2 mol NCO/mol Hb) the average increase in MLS was 8.14+/-4.9 days, 14.7+/-4.1 days, and 18.4+/-8.8 days, respectively. Analysis of survival curves and the results of an experiment using a population of Hb SS cells separated by centrifugation indicated that carbamylation had a disproportionate effect on the survival of the youngest cells in the population. Improvement in MLS correlated with the reticulocyte count of the cells carbamylated. This finding is explained on the hypothesis that the life span of irreversibly sickled and other damaged cells is not improved by carbamylation but that carbamylation greatly improves the life span of the young, and as yet undamaged, cells. For this reason extracorporeal carbamylation is not favored as a form of therapy. At the level of carbamylation attainable by oral therapy, however, it would appear likely that only a modest increase in red cell life span will be achieved.

J Clin Invest. 1968 Aug;47(8):1731-41. (PMID: 5666109)
Blood. 1969 Feb;33(2):214-24. (PMID: 5766311)
Br J Haematol. 1969 Dec;17(6):527-33. (PMID: 5362290)
J Clin Invest. 1970 Apr;49(4):623-34. (PMID: 5443167)
Biochim Biophys Acta. 1971 Jan 13;227(1):192-8. (PMID: 5543587)
Proc Natl Acad Sci U S A. 1971 Nov;68(11):2791-3. (PMID: 5288258)
Proc Natl Acad Sci U S A. 1971 Jun;68(6):1180-3. (PMID: 5288366)
Biochem J. 1971 Aug;124(1):31-45. (PMID: 5166592)
Biochem Biophys Res Commun. 1971 Sep 17;44(6):1381-7. (PMID: 4946263)
J Clin Invest. 1972 Mar;51(3):566-74. (PMID: 5011101)
Biochem Biophys Res Commun. 1972 Feb 16;46(3):1255-61. (PMID: 5012168)
Nature. 1972 Jun 9;237(5354):336-8. (PMID: 4557398)
Eur J Biochem. 1972 May;27(1):103-8. (PMID: 5049047)
Blood. 1972 Nov;40(5):733-9. (PMID: 5078929)
J Clin Invest. 1973 Feb;52(2):422-32. (PMID: 4683881)
Proc Soc Exp Biol Med. 1973 Feb;142(2):712-5. (PMID: 4570044)
Blood. 1973 May;41(5):653-60. (PMID: 4694082)
J Lab Clin Med. 1973 Jun;81(6):941-5. (PMID: 4710373)
Lancet. 1972 Mar 25;1(7752):658-61. (PMID: 4125163)
Blood. 1951 Dec;6(12):1284-92. (PMID: 14886401)
Blood. 1953 Dec;8(12):1110-36. (PMID: 13105714)
Br J Haematol. 1961 Jul;7:382-404. (PMID: 13725844)
Br J Haematol. 1962 Jan;8:15-27. (PMID: 13896771)
Bull Johns Hopkins Hosp. 1962 Jun;110:293-310. (PMID: 13911663)
J Lab Clin Med. 1963 Feb;61:249-57. (PMID: 14021763)
Blood. 1963 Jan;21:63-9. (PMID: 14021765)
Blood. 1963 Oct;22:459-65. (PMID: 14072574)

0 (Carbamates)
0 (Carbon Radioisotopes)
0 (Phosphorus Radioisotopes)
10028-17-8 (Tritium)
12UHW9R67N (Isoflurophate)

Date Created: 19731201 Date Completed: 19740111 Latest Revision: 20181113

20250114

PMC302592

10.1172/JCI107516

4750447